In this episode, we talk with Dr. Zach Waldrop about his Arkansas Health Ventures Accelerator (ARHVA) project developing genetically engineered probiotics to treat gastrointestinal diseases. His team modifies a safe yeast strain, Saccharomyces boulardii, to display antibodies that neutralize bacterial toxins, offering a potential alternative to antibiotics. Early lab tests show the engineered yeast can survive in colon-like conditions and bind harmful toxins. Waldrop envisions this as a platform technology adaptable to multiple gut infections, including E. coli, C. difficile, and cholera, with hopes of creating easy access and affordable treatment.